Amgen Inc. to acquire Dezima Pharma

October 22, 2015

De Brauw Blackstone Westbroek has advised Amgen Inc. on the USD 1.55 billion acquisition of Dezima Pharma.

Dezima is a privately held, Netherlands-based biotechnology company, focused on developing innovative treatments for dyslipidaemia. De Brauw acted as local counsel to Amgen.


Mark Rebergen (lead partner), Jasper Zents, Kees Kraaiveld, Okke Suurenbroek, Ingrid Mensing, Daniel van Gerven

We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.